Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Autor: Barker, Andrew J, Gibson, Keith H, Grundy, Walter, Godfrey, Andrew A, Barlow, Jeffrey J, Healy, Mark P, Woodburn, James R, Ashton, Susan E, Curry, Brenda J, Scarlett, Lynn, Henthorn, Lianne, Richards, Laura

Publikováno v: In Bioorganic & Medicinal Chemistry Letters 23 July 2001 11(14):1911-1914

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

Autor: Wakeling AE; Department of Cancer and Infection Research, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH

Publikováno v: Cancer research [Cancer Res] 2002 Oct 15; Vol. 62 (20), pp. 5749-54.